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Low Dose Ketamine for Opioid Refractory Cancer Pain
Michelle Nguyen MD, Anthony Grech MD
Department of Hospice and Palliative Medicine
Henry Ford Health System, Detroit, Michigan

Background
Pain is a common complication for patients with advanced cancer, occuring in up to 90%
of patients. Intractable pain has been reported in 10-20% of these patients. Cancer pain
is often of mixed etiology and may have nociceptive, neuropathic and inflammatory
components. Opioids are frequently prescribed for the management of moderate to
severe cancer pain. However, there are instances where opioids and traditional adjuvant
medications are not sufficient to control severe cancer pain. Ketamine is being used
more frequently in the hospice and palliative setting to control this opioid refractory pain.
Unfortunately there is mixed evidence in the literature and there are no widely agreed
upon guidelines for dosing.

Objectives
● To describe the successful use of sub-anesthetic ketamine in the management of high
dose opioid refractory cancer pain
● To propose a new area of study in the use of sub-anesthetic ketamine for
management of an opioid refractory cancer pain

Current HF Policy: Ketamine in ER for Pain

Case
A 32 year old male, receiving home hospice, with stage IV gastric adenocarcinoma,
complicated by severe cancer-related abdominal pain presented to the ED in a pain
crisis, agitated, confused and drowsy. His pain had been managed with a fentanyl
PCA at home, with a 650 mcg/hr continuous infusion and a 200mcg demand dose with
a 10 minute lockout. His fentanyl use escalated over the preceding days with 31,600
mcg of fentanyl (5266 oral morphine equivalents) in the 24 hours leading up to
presentation. In the ED, his fentanyl PCA was continued and he was given
hydromorphone 6mg IV and dexamethasone 10mg IV without effect. He was then
given a 0.3 mg/kg ketamine bolus with improvement of his pain. He was subsequently
admitted to the inpatient hospice unit for further pain management. He was initiated
on a low dose ketamine infusion at 0.1mg/kg/hr and was rotated to a hydromorphone
PCA at a continuous infusion of 13mg/hr (which is a 25% dose reduction from total
fentanyl use) and a 10mg demand dose and 10 minute lockout. His ketamine infusion
was titrated upwards to 0.2mg/kg/hr with improvement of his pain. He was maintained
at this rate with adequate pain control while his hydromorphone PCA was able to be
tapered down to a continuous infusion of 6mg/hr (decreased by 2mg/hr daily) and
demand dose of 8mg with a 10 minute lockout. He was subsequently weaned off the
ketamine infusion with sustained pain control and a 50% decrease in his opioid
requirement. He experienced mild non-disturbing hallucinations and vivid dreams
which were adequately controlled with haloperidol and lorazepam. The patient was
able to be discharged home with adequate pain control on the hydromorphone PCA
with home hospice.

Henry Ford Tier 1 Policy: Utilization of Low Dose Ketamine for Pain Management in
Emergency Medicine for Adults (age greater than or equal to 15 years)

Literature Review
IV ketamine as an adjunct analgesic for patients tolerant to opioids or as an alternative to
opioids in other acute and chronic pain diagnoses
○ Tumor progression, bone metastases
○ Spinal or orthopedic surgery, major limb injuries
○ Sickle cell disease
○ Cluster headaches
○ Chronic abdominal pain
Dosage for ketamine IV infusion range from 0.1-0.3 mg/kg, max 30mg.
This is what was utilized as a test bolus for this patient.

Refractory Pain
Opioid refractory cancer pain is thought to be related to the activation of N-methyl-Daspartate (NMDA) receptors in certain regions of the central nervous system. There is an
association with nociceptive activation of the NMDA receptor, clinical hyperalgesia or
allodynia and reduced opioid sensitivity. There is growing evidence that the NMDA
receptor plays an active role in the development of opioid tolerance. By blocking
activated NMDA receptor channels, it is thought that this “resets” the neuronal
hyperexcitability and subsequently reduces pain signaling.

The most recent Cochrane Review for ketamine use as an adjuvant to opioids in the
relief of refractory cancer pain concluded that there was insufficient evidence to
assess benefits and harms and that more randomized controlled trials examining
specific low dose ketamine clinical regimens are needed. There are many case
reports supporting its use for this indication. However there are few studies done
and results from them are mixed. There was one notable negative study by Hardy et
al. which utilized a rapid dose escalation to a dose higher than in most other
literature, but showed a sizable placebo effect and low number needed to harm for
adverse side effects. The heterogeneous results may be attributed to small sample
sizes and differing doses and routes of administration of ketamine. Given the mixed
results in the literature, it is likely that certain patients benefit from ketamine, while
others do not. Studies have failed to determine any factors associated with a
favorable response. No definitive association has been found with age, gender, or
pain mechanism. One study showed that most patients who benefitted were using
more than one coanalgesic, implying that pain that was less responsive to
conventional analgesics was more responsive to ketamine.

Pharmacology of Ketamine
Ketamine is a potent NMDA antagonist, and therefore may reduce opioid
tolerance by blocking activation of this receptor. It acts by binding and blocking
NMDA receptor channels when they are in the open, activated state as well as
binding to a secondary site, which reduces the frequency of channel openings. It
is 10-fold stronger than methadone as an NMDA antagonist and exerts its
analgesic effects through many other non-NMDA binding sites including
muscarinic and nicotinic acetylcholine receptors, voltage-gated calcium channels,
D2 dopamine receptors and GABA receptors. In sub-anesthetic doses, the patient
remains awake and responsive while experiencing significant analgesia. The IV
onset of action is within seconds, and the half-life is 2-3 hours.
Side effects of ketamine include dysphoria, misperceptions, hallucinations, and
alterations in body or mood. Sub-anesthetic doses are commonly associated with
mild and transient impairments in attention, memory and judgement. These
effects can generally be controlled by low doses of benzodiazepine or haloperidol.
Mild increases in heart rate or blood pressure can occur. Naloxone does not
reverse the analgesic effects or side effects of ketamine.

Proposal for Future Study
Given the mixed results in the literature, it would be beneficial to determine if a certain
population of patients would benefit the most from the use of ketamine as an adjunct in
the treatment of opioid refractory cancer pain. In order to better identify this population,
we propose the use of a test bolus. This could use the bolus infusion described in Henry
Ford’s Tier 1 policy for low dose ketamine for pain management in the emergency
department. We propose administering this to a patient being considered for ketamine
treatment in the setting of a pain crisis. If the patient has a good response to the test
bolus, then the patient can be started on a continuous infusion as this may mean it is
more likely to be efficacious. We hypothesize that by using this test bolus to select the
patient population, this may help yield more definitive results on the utility of ketamine
in the treatment of opioid refractory cancer pain and shed some light onto which patients
would benefit most.
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